Shanghai HaiHe Pharmaceutical Co., Ltd.

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

Who: Gilead Sciences/Everest Medicines What: Gilead subsidiary Immunomedics will acquire the remaining worldwide rights to its “pipeline-in-a-product,” Trodelvy, from Everest, which has rights for

A dearth of innovative drug developers seeking public listings on China’s Nasdaq-like STAR Market has made investors scratch their heads, as the bourse, hailed as the country’s only stock market open

[ Editor's note: A version of this article was originally published in Informa's Scrip .] Previously partnered on companion diagnostic development for ovarian and breast cancer, AstraZeneca will